Peri-operative Safety and Complications of Central Venous Access Device in Paediatric-Haemato-Oncology Patients: A Single-Centre Experience of 180 Procedures with Special Focus on Chemoport Insertion.

IF 0.7 Q4 ONCOLOGY
Indian Journal of Surgical Oncology Pub Date : 2026-06-01 Epub Date: 2025-10-15 DOI:10.1007/s13193-025-02449-8
Akhil Palod, Vasudeva K Bhat, Roshan George Rajan, Ananth S Mathad, Naveena A N Kumar
{"title":"Peri-operative Safety and Complications of Central Venous Access Device in Paediatric-Haemato-Oncology Patients: A Single-Centre Experience of 180 Procedures with Special Focus on Chemoport Insertion.","authors":"Akhil Palod, Vasudeva K Bhat, Roshan George Rajan, Ananth S Mathad, Naveena A N Kumar","doi":"10.1007/s13193-025-02449-8","DOIUrl":null,"url":null,"abstract":"<p><p>Reliable long-term central venous access is a cornerstone in the management of paediatric haematology and oncology patients. The use of chemoport in paediatric populations remains limited, primarily due to concerns regarding peri-procedural risks and associated complications. We aim to present our experience of central venous access device (CVAD) in paediatric-haemato-oncology patients with special focus on chemoport insertion, with respect to standardisation of technique, peri-procedural safety, and complications. The paediatric haematology and oncology patients who underwent CVAD insertion between June 2019 and June 2025 were included in the study. The data were retrospectively reviewed from a prospectively maintained department database. The variables included patient demographics, indication, site, route of insertion, technique used, and peri-operative complications. A total of 180 CVAD insertions were performed in paediatric patients between June 2019 and June 2025. Among them, 155 (86.1%) had haematolymphoid malignancies, and 25 (13.9%) had solid tumours. The youngest patient was 4 months old and the eldest was 18 years. Of the 180 CVAD insertions, 140 were chemoport insertions, 29 received Hickman lines, and 11 were subclavian lines. Among the chemoport recipients, six patients (4.3%) had complications, which included: one had a guidewire-associated right atrial rupture, which was managed by emergency thoracotomy; two developed pneumothorax requiring intercostal drainage, and three had minor complications such as port-site erythema and post-procedural fever, managed conservatively. All patients recovered uneventfully and commenced treatment without delay. Totally implantable devices such as chemoports are safe and reliable for paediatric patients with haematological and solid malignancies. Although associated with a learning curve and potential procedural risks, these can be minimised through standardised techniques, protocol-driven care, and continuous personnel training.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 6","pages":"1428-1434"},"PeriodicalIF":0.7000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13315040/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Surgical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13193-025-02449-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Reliable long-term central venous access is a cornerstone in the management of paediatric haematology and oncology patients. The use of chemoport in paediatric populations remains limited, primarily due to concerns regarding peri-procedural risks and associated complications. We aim to present our experience of central venous access device (CVAD) in paediatric-haemato-oncology patients with special focus on chemoport insertion, with respect to standardisation of technique, peri-procedural safety, and complications. The paediatric haematology and oncology patients who underwent CVAD insertion between June 2019 and June 2025 were included in the study. The data were retrospectively reviewed from a prospectively maintained department database. The variables included patient demographics, indication, site, route of insertion, technique used, and peri-operative complications. A total of 180 CVAD insertions were performed in paediatric patients between June 2019 and June 2025. Among them, 155 (86.1%) had haematolymphoid malignancies, and 25 (13.9%) had solid tumours. The youngest patient was 4 months old and the eldest was 18 years. Of the 180 CVAD insertions, 140 were chemoport insertions, 29 received Hickman lines, and 11 were subclavian lines. Among the chemoport recipients, six patients (4.3%) had complications, which included: one had a guidewire-associated right atrial rupture, which was managed by emergency thoracotomy; two developed pneumothorax requiring intercostal drainage, and three had minor complications such as port-site erythema and post-procedural fever, managed conservatively. All patients recovered uneventfully and commenced treatment without delay. Totally implantable devices such as chemoports are safe and reliable for paediatric patients with haematological and solid malignancies. Although associated with a learning curve and potential procedural risks, these can be minimised through standardised techniques, protocol-driven care, and continuous personnel training.

儿科-血液-肿瘤患者中心静脉通路装置的围手术期安全性和并发症:180例手术的单中心经验,特别关注化疗孔插入。
可靠的长期中心静脉通路是儿科血液病和肿瘤患者管理的基石。在儿科人群中,化疗的使用仍然有限,主要是由于对围手术期风险和相关并发症的担忧。我们的目的是介绍中心静脉通路装置(CVAD)在儿科-血液-肿瘤患者中的应用经验,特别是在化学通道插入方面,涉及技术标准化、术中安全性和并发症。在2019年6月至2025年6月期间接受CVAD植入的儿科血液学和肿瘤学患者被纳入研究。数据是从前瞻性维护的部门数据库中回顾性审查的。变量包括患者人口统计学、适应证、部位、插入途径、使用的技术和围手术期并发症。2019年6月至2025年6月期间,在儿科患者中共进行了180次CVAD植入。其中,155例(86.1%)为淋巴细胞恶性肿瘤,25例(13.9%)为实体瘤。最小的患者4个月大,最大的18岁。180例CVAD插入中,140例为化合孔插入,29例为Hickman系,11例为锁骨下系。在接受化疗的患者中,6名患者(4.3%)出现并发症,其中包括:1名患者发生导丝相关的右心房破裂,经紧急开胸处理;2例发展为气胸,需要肋间引流,3例有轻微并发症,如肝部位红斑和术后发热,保守处理。所有患者均顺利康复,并立即开始治疗。对于患有血液病和实体恶性肿瘤的儿童患者,完全植入式装置(如chemoports)是安全可靠的。尽管与学习曲线和潜在的程序风险相关,但可以通过标准化技术、协议驱动的护理和持续的人员培训将其降至最低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
190
期刊介绍: The Indian Journal of Surgical Oncology aims to encourage and promote clinical and research activities pertaining to Surgical Oncology. It also aims to bring in the concept of multidisciplinary team approach in management of various cancers. The Journal would publish original article, point of technique, review article, case report, letter to editor, profiles of eminent teachers, surgeons and instititions - a short (up to 500 words) of the Cancer Institutions, departments, and oncologist, who founded new departments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书